表紙:市場のスポットライト:座瘡
市場調査レポート
商品コード
997347

市場のスポットライト:座瘡

Market Spotlight: Acne

出版日: | 発行: Datamonitor Healthcare | ページ情報: 英文 46 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.84円
市場のスポットライト:座瘡
出版日: 2021年03月15日
発行: Datamonitor Healthcare
ページ情報: 英文 46 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界の座瘡罹患件数は2019年に約6億1,250万件と推定されており、その数は2028年までに6億5,860万件に増加すると予測されています。

座瘡分野で承認された薬は、さまざまなターゲットに焦点を当てています。これらの薬は、経口および局所経路で投与されます。

座瘡の積極的な臨床開発において業界が後援する薬剤の大部分はフェーズIIにあり、NDA / BLA段階にある製品は1つだけです。

この市場スポットライトレポートは、座瘡に関する主要な市販薬とパイプライン薬、最近のイベントとアナリストの意見、臨床試験、今後の規制イベント、成功の可能性、10年間の疾患有病率予測、ライセンシングと買収の取引、および薬剤固有の収益予測など、座瘡市場の概要などを提供しています。

目次

内容

概要

重要なポイント

病気の背景

治療

  • 局所療法
  • 全身療法
  • 物理的治療

疫学

市販薬

パイプライン薬

最近の出来事とアナリストの意見

  • 座瘡のためのVB1953(2020年6月16日)
  • 座瘡のためのDMT310(2020年6月10日)
  • 座瘡のためのFCD105(2020年6月2日)
  • 座瘡のためのTwyneo(2019年12月30日)

今後の主なイベント

主要な規制イベント

  • CassiopeaのWinleviは座瘡市場に新薬クラスをもたらす

成功の確率

ライセンシングおよび資産取得の取引

  • GSKがEligoと皮膚科関連で契約締結
  • L'Orealの微生物叢探査が、次世代抗菌剤についてMicreoとの取引につながる
  • Paratek、中国に座瘡薬をもたらすためのAlmirallパートナー

収益機会

臨床試験の情勢

  • ステータス別のスポンサー
  • フェーズ別のスポンサー
  • 最近のイベント

参考文献

  • 処方情報

付録

図のリスト

表のリスト

目次
Product Code: DMKC0181187

This Market Spotlight report covers the Acne market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

Datamonitor Healthcare estimates that in 2019, there were approximately 612.5 million prevalent cases of acne worldwide, and forecasts that number to increase to 658.6 million prevalent cases by 2028.

Approved drugs in the acne space focus on a wide variety of targets. These drugs are administered via the oral and topical routes.

The majority of industry-sponsored drugs in active clinical development for acne are in Phase II, with just a single product in the NDA/BLA stage.

Therapies in development for acne focus on a wide variety of targets. The majority of the pipeline drugs are administered via the topical route, with the remainder being oral, subcutaneous, intranasal, or intravenous formulations.

The only high-impact upcoming event for drugs in the acne space is an expected PDUFA date for Twyneo. The overall likelihood of approval of a Phase I dermatology-general asset is 20.2%, and the average probability a drug advances from Phase III is 68%. Drugs, on average, take 8.8 years from Phase I to approval in the dermatology-general space, as well as in the overall dermatology space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for acne have been in the late phases of development, with 52% of trials in Phase III-IV, and 48% in Phase I-II.

The US has a substantial lead in the number of acne clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.

Clinical trial activity in the acne space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for acne, with 35 trials.

GlaxoSmithKline leads industry sponsors with by far the highest overall number of clinical trials for acne, followed by AbbVie.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Topical therapy
  • Systemic therapy
  • Physical treatments

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • VB 1953 for Acne (June 16, 2020)
  • DMT310 for Acne (June 10, 2020)
  • FCD105 for Acne (June 2, 2020)
  • Twyneo for Acne (December 30, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Cassiopea's Winlevi Brings New Drug Class To Acne Market

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • GSK Inks Dermatology Pact With Eligo
  • L'Oreal's Microbiome Explorations Lead To Micreos Deal For Next-Gen Antibacterial
  • Paratek, Almirall Partner To Bring Acne Medicine To China

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of acne, 2019-28
  • Figure 2: Overview of pipeline drugs for acne in the US
  • Figure 3: Pipeline drugs for acne, by company
  • Figure 4: Pipeline drugs for acne, by drug type
  • Figure 5: Pipeline drugs for acne, by classification
  • Figure 6: VB 1953 for Acne (June 16, 2020): Phase II - Facial Acne Vulgaris
  • Figure 7: DMT310 for Acne (June 10, 2020): Phase IIb - 003
  • Figure 8: FCD105 for Acne (June 2, 2020): Phase II - Acne Vulgaris
  • Figure 9: Twyneo for Acne (December 30, 2019): Phase III - SGT-65-04, Phase III - SGT-65-05
  • Figure 10: Key upcoming events in acne
  • Figure 11: Probability of success in the dermatology-general pipeline
  • Figure 12: Clinical trials in acne
  • Figure 13: Top 10 drugs for clinical trials in acne
  • Figure 14: Top 10 companies for clinical trials in acne
  • Figure 15: Trial locations in acne
  • Figure 16: Acne trials status
  • Figure 17: Acne trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of acne, 2019-28
  • Table 2: Marketed drugs for acne
  • Table 3: Pipeline drugs for acne in the US
  • Table 4: VB 1953 for Acne (June 16, 2020)
  • Table 5: DMT310 for Acne (June 10, 2020)
  • Table 6: FCD105 for Acne (June 2, 2020)
  • Table 7: Twyneo for Acne (December 30, 2019)
  • Table 8: Historical global sales, by drug ($m), 2015-19
  • Table 9: Forecasted global sales, by drug ($m), 2021-25